Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The aim of the phase II Nivothym study is to collect data on activity and toxicity of
nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously
received a first platinum-based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC